BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
The Company made the application in connection with its default with respect to having not filed its audited annual financial statements for the year ended October 31, 2023, along with management's discussion and analysis relating to the audited annual financial statements for the year ended October 31, 2023, and certification of the foregoing filings as required by National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings (collectively, the "Required Reports") by the reporting deadline of February 28, 2024. The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company
The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company
The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order. The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.
As previously announced, the Company's filing of the Required Reports has been delayed as both management and its external auditor, Dale Matheson Carr-Hilton LaBonte LLP ("DMCL"), agreed that additional information and analysis is necessary to complete the Required Reports and DMCL's review of such Required Reports. One of the factors contributing to the delay is the recent unexpected departures of the Chief Financial Officer of the Company as announced on June 30th, 2023, as the Company experienced delays in its ability to provide the necessary documentation to complete internal pre-audit procedures associated with the audit process.  A further factor contributing to the delay is the recent acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets of former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA on February 16th, 2024. The Company and its' external auditor, DMCL, believe that this  acquisition constitutes a major purchase of assets that must be reported in its financial statement in accordance with IAS 10. Pursuant to IAS 10, adopted on April 2001 by the International Accounting Standards Board, the financial reporting of events after the reporting period under Section 22(c) of IAS 10 include the category of major purchases of assets
Pursuant to IAS 10, adopted on April 2001 by the International Accounting Standards Board, the financial reporting of events after the reporting period under Section 22(c) of IAS 10 include the category of major purchases of assets

Source prnewswire